KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Research & Development: 2011-2022

Historic Research & Development for TherapeuticsMD (TXMD) over the last 10 years, with Sep 2022 value amounting to $1.1 million.

  • TherapeuticsMD's Research & Development fell 30.72% to $1.1 million in Q3 2022 from the same period last year, while for Sep 2022 it was $5.5 million, marking a year-over-year decrease of 31.61%. This contributed to the annual value of $7.1 million for FY2021, which is 32.07% down from last year.
  • TherapeuticsMD's Research & Development amounted to $1.1 million in Q3 2022, which was down 29.62% from $1.6 million recorded in Q2 2022.
  • TherapeuticsMD's Research & Development's 5-year high stood at $7.0 million during Q1 2018, with a 5-year trough of $1.1 million in Q3 2022.
  • In the last 3 years, TherapeuticsMD's Research & Development had a median value of $2.0 million in 2021 and averaged $2.0 million.
  • As far as peak fluctuations go, TherapeuticsMD's Research & Development increased by 4.22% in 2018, and later slumped by 50.29% in 2020.
  • TherapeuticsMD's Research & Development (Quarterly) stood at $6.8 million in 2018, then slumped by 34.37% to $4.4 million in 2019, then tumbled by 45.98% to $2.4 million in 2020, then crashed by 40.69% to $1.4 million in 2021, then plummeted by 30.72% to $1.1 million in 2022.
  • Its Research & Development stands at $1.1 million for Q3 2022, versus $1.6 million for Q2 2022 and $1.4 million for Q1 2022.